81 related articles for article (PubMed ID: 20715915)
1. General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals.
Goeree R; O'Reilly D; Hopkins R; Blackhouse G; Tarride JE; Xie F; Lim M
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):379-84. PubMed ID: 20715915
[TBL] [Abstract][Full Text] [Related]
2. The impact of diabetes mellitus on healthcare costs in Italy.
Giorda CB; Manicardi V; Diago Cabezudo J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-19. PubMed ID: 22098288
[TBL] [Abstract][Full Text] [Related]
3. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
4. [Disease modelling in diabetes mellitus].
Schramm W; Schöffski O; Görtz A; Liebl A
Dtsch Med Wochenschr; 2004 Oct; 129(43):2305-10. PubMed ID: 15483770
[TBL] [Abstract][Full Text] [Related]
5. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
Hoerger TJ
Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
[TBL] [Abstract][Full Text] [Related]
6. The economic imperative to conquer diabetes.
Fradkin J; Rodgers GP
Diabetes Care; 2008 Mar; 31(3):624-5. PubMed ID: 18308686
[No Abstract] [Full Text] [Related]
7. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
9. [An economic review of the management of diabetes mellitus].
Tsujii S
Nihon Rinsho; 2002 Oct; 60 Suppl 10():623-30. PubMed ID: 12430293
[No Abstract] [Full Text] [Related]
10. The quality of three decision-analytic diabetes models: a systematic health economic assessment.
Becker C; Langer A; Leidl R
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):751-62. PubMed ID: 22098291
[TBL] [Abstract][Full Text] [Related]
11. Adjusting for bias in C/E ratio estimates.
Stinnett AA
Health Econ; 1996; 5(5):470-2. PubMed ID: 8922973
[TBL] [Abstract][Full Text] [Related]
12. Economics of diabetes mellitus.
Krein SL; Funnell MM; Piette JD
Nurs Clin North Am; 2006 Dec; 41(4):499-511, v-vi. PubMed ID: 17059971
[TBL] [Abstract][Full Text] [Related]
13. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
14. How should developing countries manage diabetes?
Narayan KM; Zhang P; Williams D; Engelgau M; Imperatore G; Kanaya A; Ramachandran A
CMAJ; 2006 Sep; 175(7):733. PubMed ID: 17001048
[No Abstract] [Full Text] [Related]
15. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
16. Lifetime health effects and costs of diabetes treatment.
Niessen LW; Dijkstra R; Hutubessy R; Rutten GE; Casparie AF
Neth J Med; 2003 Nov; 61(11):355-64. PubMed ID: 14768718
[TBL] [Abstract][Full Text] [Related]
17. [Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study].
Köster I; Hauner H; von Ferber L
Dtsch Med Wochenschr; 2006 Apr; 131(15):804-10. PubMed ID: 16607599
[TBL] [Abstract][Full Text] [Related]
18. [Update on current care guidelines: diabetes].
Duodecim; 2012; 128(2):180-2. PubMed ID: 22372072
[TBL] [Abstract][Full Text] [Related]
19. Predictive Model for Estimating the Cost of Incident Diabetes Complications.
Zhu J; Kahn P; Knudsen J; Mehta SN; Gabbay RA
Diabetes Technol Ther; 2016 Oct; 18(10):625-634. PubMed ID: 27583583
[TBL] [Abstract][Full Text] [Related]
20. Adjusting for comorbidities in cost of illness studies.
Rizzo JA; Chen J; Gunnarsson CL; Naim A; Lofland JH
J Med Econ; 2015 Jan; 18(1):12-28. PubMed ID: 25253504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
